Pharmaceuticals #fda#peptides
FDA Panel Endorses Unproven Peptides, Opening Door for Compounding Pharmacy Manufacturing
An FDA advisory panel voted 8-6 to recommend reclassifying three unproven peptides—BPC-157, KPV, and TB-500—allowing compounding pharmacies to produce them. A fourth peptide, MOTs-C, received a 7-5 vote in favor. The decision could reshape pharmaceutical manufacturing supply chains, as China and India are major suppliers of these peptides.
Jul 23, 2026 1 source